[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621101":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":27,"locations":37,"responsibleParty":48,"collaborators":52,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":10,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":10,"overallStatus":69,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Assiut University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A chemo naive and Group B neoadjuvant group",null,"Group A (Chemo-naïve group) 36 Patients who underwent primary debulking surgery (PDS) followed by adjuvant platinum-based chemotherapy.\n\nGroup B (Neoadjuvant group) 36 Patients who received 3-4 cycles of platinum-based neoadjuvant chemotherapy followed by interval debulking surgery (IDS).",[13,14],"Other: Immunohistochemical (IHC) assessment of DHODH expression","Other: No interventions as it is observational study",{"label":16,"type":10,"description":11,"interventionNames":17},"Group A (Chemo-naïve group) 36 Patients and Group B (neoadjuvant) group",[13,14],[19,23],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Immunohistochemical (IHC) assessment of DHODH expression","Comparative analysis of DHODH expression in adjuvant and neoadjuvant groups and correlate its expression with clinical outcomes",[16,9],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"No interventions as it is observational study","No interventions as itis observational study",[16,9],[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"heba ahmed mohamed, demonstrator","CONTACT","01151056041","heba.ahmed17199d@gmail.com",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"dalia mohamed mohsen, Prof.Dr","01066189050","daliabadary@aun.edu.eg",[38],{"facility":5,"status":10,"city":39,"state":10,"zip":10,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":10},"Asyut","Egypt","EG",{"type":43,"coordinates":44},"Point",[45,46],31.18368,27.18096,{"lat":46,"lon":45},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Heba Ahmed Mohamed","demonstrator",[53],{"name":5,"class":6},"100621101","prognostic-value-of-dhodh-expression-in-hgsoc-a-comparative-study-between-neoadjuvant-and-adjuvant-chemotherapy-settings-100621101",false,"NCT07366242","Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings","Prognostic Value of Dihydroorotate Dehydrogenase (DHODH) Expression in High-Grade Serous Ovarian Carcinoma: A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings","HGSOC","Inclusion Criteria:\n\n* Histologically confirmed high-grade serous ovarian carcinoma\n* Availability of adequate FFPE tumor tissue\n* Known treatment modality (PDS or IDS)\n* Available clinical follow-up including platinum-free interval and survival data\n\nExclusion Criteria:\n\n* Non-serous histological subtypes\n* Low-grade serous carcinoma\n* Inadequate tissue for immunohistochemistry\n* Missing clinical or follow-up data","FEMALE",{"count":64,"type":65},72,"ESTIMATED","OBSERVATIONAL","* To compare DHODH protein expression in HGSC tissues from patients undergoing Primary Debulking Surgery (PDS - Chemo-naive) versus Interval Debulking Surgery (IDS - Post-NACT).\n* To evaluate the association between DHODH expression and the degree of chemotherapy response (using the Chemotherapy Response Score - CRS for NACT cases).\n* To determine the prognostic value of DHODH expression in predicting Platinum-Free Interval (PFI) ,Progression -Free Survival (PFS) and Overall Survival (OS) across both groups.",[60],"NOT_YET_RECRUITING","2026-01-16",{"date":72,"type":73},"2026-01-26","ACTUAL",{"date":75,"type":65},"2026-06-01",{"date":77,"type":65},"2027-07-01",{"name":50,"class":6},1]